Abstract: Provided herein are microparticles and compositions comprising Poly(I:C) and/or polyinosinic acid (Poly I) and polycytidylic acid (Poly C) for use in preventing viral infections of the upper respiratory tract, such as human rhinovirus infection or an influenza virus infection. A nasal delivery device comprising a composition of the invention is also described.

Abstract: Disclosed are medicaments, pharmaceutical compositions, pharmaceutical kits, and methods based on combinations of at least one HCV protease inhibitor and at least one HCV polymerase inhibitor but not HCV-796; for concurrent or consecutive administration in treating or ameliorating one or more symptoms of HCV, or disorders associated with HCV in a subject in need thereof.

Abstract: Controlled-release dosage formulations including at least one compound of Formulae I to XXVIII herein and a controlled-release carrier and methods of treatment using the same are provided.

Abstract: Novel hepatitis C virus (“HCV”) inhibitor combinations comprising an HCV protease inhibitor and HCV polymerase inhibitor, and optionally one or more biologically active agents, as well as uses of these combinations as HCV inhibitors and for treating hepatitis C and related disorders are disclosed.

Abstract: The present application relates to methods for growing crystals of both the uncomplexed and complexed forms of ?-secretase (BACE) polypeptide. The present application also relates to crystalline forms of uncomplexed BACE and the three-dimensional structure of BACE, as determined from the crystals. In addition, the present application relates to the use of crystalline forms of BACE to identify ligands, preferably inhibitors (antagonists), which bind to, and preferably inhibit the enzymatic activity of, BACE. Furthermore, the present application relates to nucleic acid sequences encoding BACE polypeptide, and methods for making BACE in greater quantity than prior methods, resulting in more effective crystallization.

Abstract: Pharmaceutical formulations containing at least one compound of Formulae I-XXVI herein and at least one surfactant. Pharmaceutically acceptable carriers and excipients may also be included in the formulations. The formulations of the present invention are suited for use in single unit dosages.

Abstract: A method of treating, preventing or ameliorating one or more symptoms associated with hepatitis C virus (HCV) in a patient in whom either the HCV is of Genotype 1 and/or the patient was previously treated with interferon and the previous interferon therapy was ineffective to treat the one or more symptoms associated with HCV, comprising administering to such a patient an effective amount of at least one compound of formulae I-XXVI of which the following structural formula is exemplary or a pharmaceutically acceptable salt, solvate or ester thereof. Optional combined administration of said at least one compound with an interferon or pegylated interferon and/or ribaviron is also contemplated.

Abstract: A method of treating, preventing or ameliorating one or more symptoms of hepatitis C, or inhibiting cathepsin activity, in a subject is provided, in which at least one compound (e.g., a HCV protease inhibitor) is administered in one or more discrete dosages over a twenty-four hour time interval in an asymmetric pattern as to dosage amount and/or timing of dosage, wherein the at least one compound is selected from the group consisting of compounds of Formulae I-XXVI, described herein. Methods of modulating the activity of hepatitis C virus protease in a subject are also provided. Asymmetric dosing as to amount of dose and/or timing of dose permits adjustment of dosing to accommodate variations in drug metabolism and/or viral activity caused by viral cell division or a patient's circadian rhythms, thus delivering the maximum amount of dose at the time or times it is most effective.

Abstract: Methods are provided for using at least one novel hepatitis C (“HCV”) protease inhibitor in combination with at least one antiviral and/or immunomodulatory agent, which is different from the at least one HCV protease inhibitor, for treating a wide variety of diseases or disorders associated with hepatitis C virus by modulating the activity of HCV protease (for example HCV NS3/NS4a serine protease) and reducing HCV viral load in a subject in a reduced treatment period. With the present invention, a hepatitis C viral load is reduced in a subject to a concentration of less than 6×10?5 HCV virions per milliliter of plasma in a time period of less than or equal to about 24 weeks. With the present invention, a hepatitis C viral production is suppressed with an effectiveness in a range of 0.7 to 0.997.

Abstract: Methods for preventing, ameliorating or treating one or more symptoms of Hepatitis C virus (HCV), modulating HCV protease activity and/or inhibiting cathepsin activity in a subject, wherein the methods comprise administering to a subject in need of such treatment a dosage formulation containing at least one compound of Formulae I-XXVI herein, wherein the dosage formulation is capable of maintaining an average Cmin plasma concentration of the compound at or above 10 ng/ml.

Abstract: Controlled-release dosage formulations including at least one compound of Formulae I to XXVI herein and a controlled-release carrier and methods of treatment using the same are provided.

Abstract: The present invention provides methods of inhibiting cathepsin activity in a subject in need thereof comprising administering to said subject an effective amount of at least one compound of various formulae (e.g., formula I-XXVI) disclosed herein. The present invention also provides methods of treatment of various diseases utilizing the foregoing compounds.

Abstract: The present invention provides methods for treating infections, in a host, by viruses belonging to the Flaviviridae family, such as HCV, comprising administering an Ara-C homologue to the host.

Abstract: Disclosed are medicaments containing, separately or together, (A) Pleconaril or a pharmaceutically acceptable salt thereof and (B) a pharmaceutically active agent for simultaneous, sequential or separate administration in the treatment of a viral infection and/or other disease states and the symptoms associated therewith.

Abstract: The invention relates to a leg assembly for an offshore structure, such as a self-elevating jack-up rig. The leg assembly has a pair of parallel leg chords divided into a plurality of sections by transverse bracing members. A unit of angular bracing members is secured within each such section. The unit has four angular members defining a rhombus, with each angular bracing member attached to a transverse bracing member and an adjacent leg chord. The braces are connected at four points to each other. The leg assembly is free from obstructing, drag-increasing auxiliary braces.

Abstract: The invention relates to a semi-submersible vessel designed to operate in harsh environment. The vessel has a twin-hull pontoon structure that supports four corner caissons extending vertically from the pontoons above an operational draft of the vessel. A pair of slender parallel horizontal braces connects each pair of opposing caissons, the braces extending in a general plane perpendicular to longitudinal axes of the pontoons. One of the pair of braces is secured between the forward columns and another of the pair of braces is secured between the aft columns. The braces reduce spreading and torque-induced forces acting on the columns, while not substantially increasing water plane area of the vessel. Each brace has an internal “redundancy” feature, being divided into two independent watertight compartments to continue providing buoyancy to the structure if one of the compartments is breached.

Abstract: The invention relates to a semi-submersible vessel designed to operate in harsh environment. The vessel has a twin-hull pontoon structure that supports four corner caissons extending vertically from the pontoons above an operational draft of the vessel. A pair of slender parallel horizontal braces connects each pair of opposing caissons, the braces extending in a general plane perpendicular to longitudinal axes of the pontoons. One of the pair of braces is secured between the forward columns and another of the pair of braces is secured between the aft columns. The braces reduce spreading and torque-induced forces acting on the columns, while not substantially increasing water plane area of the vessel. Each brace has an internal “redundancy” feature, being divided into two independent watertight compartments to continue providing buoyancy to the structure if one of the compartments is breached.

Abstract: Programmable attenuators including DPDT relays or pairs of SPDT relays with terminals which are interconnected through conductors and attenuator sections disposed on opposite sides of grounded isolation elements, and so configured and supported by printed circuit boards or the like as to provide very high isolation while obtaining flat response characteristics up to very high frequencies, in the megahertz range.

Abstract: A sequenced, directional restraint system for an inflatable evacuation slide wherein three separate restraints are provided across the width of the fluid distensible member of the inflatable evacuation slide and a sequenced, directional method of deploying an inflatable evacuation slide from an elevated egress to a lower surface.